1004P Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability
Overman, M.J., Leoni, G., D'Alise, A.M., Cotugno, G., Langone, F., Capone, S., Del Sorbo, M., Fakih, M., Le, D.T., Shields, A.F., Pedersen, K.S., Shah, M.A., Mukherjee, S., Delaite, P., Faivre, T., Scarselli, E.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article